Mesoblast Limited
MESOHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Mesoblast Limited (MESO) is listed under Biotechnology. Valued at $2.24B, MESO is a mid-cap name in its sector. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Market Cap
$2.24B
Beta
0.80
P/E (TTM)
—
P/E (Fwd)
-288.67
EPS (TTM)
$-0.82
EPS (Fwd)
$-0.06
ROE
-18.2%
ROA
-6.2%
Cash
$130.0M
Total Debt
$135.1M
Free CF
-$69.4M
52W Change
10.9%
Annual Financials
Cash vs Debt
Mesoblast Limited carries $135.1M in total debt against $130.0M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$69.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -18.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $10.2M to $17.2M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Mesoblast Limited's trajectory.